By blocking HERV-derived envelope proteins, temelimab significantly reduces microglial activation [51,81], a critical initial step in the neuroinflammatory cascade observed in multiple sclerosis and other neurodegenerative disorders. This evidence concerns the gene ERVW-1 and multiple sclerosis.